Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | Director · Chief Executive Officer | January 12, 2024 | January 17, 2024 |
| GERON CORPGERN · Entity 4989 | Director · President and CEO | August 07, 2025 | August 08, 2025 |
| IMMUNOMEDICS INCIMMU · Entity 145732 | Director · President and CEO | April 16, 2020 | April 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date January 12, 2024 · Filed January 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11 · Expires 2034-01-11 | Direct | 695,000 |
Reported balance
After 2024-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-12 · Grant · Acquired 695,000 · Balance 695,000 F1: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
GERON CORP
Report date August 07, 2025 · Filed August 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2035-08-06 | Direct | 7,000,000 |
Reported balance
After 2025-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-07 · Grant · Acquired 7,000,000 · Balance 7,000,000 F1: The options vest as follows: 875,000 shares on February 7, 2026, the remaining 6,125,000 shares in a series of 42 equal monthly installments commencing February 7, 2026, provided the optionee continues to provide services to the Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2035-08-06 | Direct | 4,000,000 |
Reported balance
After 2025-08-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-07 · Grant · Acquired 4,000,000 · Balance 4,000,000 F2: The options vest as follows: 1,000,000 shares on August 7, 2026, the remaining 3,000,000 shares in a series of 36 equal monthly installments commencing August 7, 2026, provided the optionee continues to provide services to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows: 875,000 shares on February 7, 2026, the remaining 6,125,000 shares in a series of 42 equal monthly installments commencing February 7, 2026, provided the optionee continues to provide services to the Company.
F2: The options vest as follows: 1,000,000 shares on August 7, 2026, the remaining 3,000,000 shares in a series of 36 equal monthly installments commencing August 7, 2026, provided the optionee continues to provide services to the Company.
IMMUNOMEDICS INC
Report date April 16, 2020 · Filed April 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par value per shareSEC Table I · non-derivative | Direct | 50,075 |
Reported balance
After 2020-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-04-16 · Grant · Acquired 50,075 · Balance 50,075 F1: Harout Semerjian was granted restricted stock units pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). 1/2 of the restricted stock units vest on each of the first and second anniversary of the date of grant, subject to Mr. Semerjian's continued service as the Company's President and Chief Executive Officer. F2: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.97 · Expires 2027-04-16 | Direct | 252,602 |
Reported balance
After 2020-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-16 · Grant · Acquired 252,602 · Balance 252,602 F3: Mr. Semerjian was granted stock options pursuant to the Plan. The stock options vest 25% on the first anniversary of the date of grant, and on a quarterly basis thereafter over a three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Harout Semerjian was granted restricted stock units pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). 1/2 of the restricted stock units vest on each of the first and second anniversary of the date of grant, subject to Mr. Semerjian's continued service as the Company's President and Chief Executive Officer.
F2: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock.
F3: Mr. Semerjian was granted stock options pursuant to the Plan. The stock options vest 25% on the first anniversary of the date of grant, and on a quarterly basis thereafter over a three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2025 Filed Aug 8, 2025 20:15 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 4,000,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0000886744-25-000062 · wk-form4_1754684133.xml · derivative · entry 2 Semerjian Harout · CIK 0001809747 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2035-08-06 F2 · derivative.exercise_date: The options vest as follows: 1,000,000 shares on August 7, 2026, the remaining 3,000,000 shares in a series of 36 equal monthly installments commencing August 7, 2026, provided the optionee continues to provide services to the Company. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 20:15 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 7,000,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0000886744-25-000062 · wk-form4_1754684133.xml · derivative · entry 1 Semerjian Harout · CIK 0001809747 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000,000 Underlying: Common Stock · 7,000,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: The options vest as follows: 875,000 shares on February 7, 2026, the remaining 6,125,000 shares in a series of 42 equal monthly installments commencing February 7, 2026, provided the optionee continues to provide services to the Company. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 16:05 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 695,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-24-001741 · doc4.xml · derivative · entry 1 Semerjian Harout · CIK 0001809747 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,000 Underlying: Common Stock · 695,000 shares Expires 2034-01-11 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 16:04 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 651,200 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-23-004218 · doc4.xml · derivative · entry 1 Semerjian Harout · CIK 0001809747 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,200 Underlying: Common Stock · 651,200 shares Expires 2033-01-18 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 19, 2024 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 16:13 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 25,000 | $1.29 | $32,250.00 |
DisclosureSEC source: 0001209191-22-056581 · doc4.xml · nonDerivative · entry 1 Semerjian Harout · CIK 0001809747 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.27 to $1.29 per share, with a weighted average purchase price of $1.29 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 20:58 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 423,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004880 · doc4.xml · derivative · entry 1 Semerjian Harout · CIK 0001809747 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,500 Underlying: Common Stock · 423,500 shares Expires 2032-01-20 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 16:41 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock option (right to buy) · Derivative | 252,602 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001104659-20-048727 · a4.xml · derivative · entry 2 Semerjian Harout · CIK 0001809747 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,602 Underlying: Common Stock, Par value $0.01 per share · 252,602 shares Expires 2027-04-16 F3 · derivative.exercise_date: Mr. Semerjian was granted stock options pursuant to the Plan. The stock options vest 25% on the first anniversary of the date of grant, and on a quarterly basis thereafter over a three year period. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 16:41 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantCommon Stock, $0.01 par value per share | 50,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-048727 · a4.xml · nonDerivative · entry 1 Semerjian Harout · CIK 0001809747 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,075 F1 · date: Harout Semerjian was granted restricted stock units pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). 1/2 of the restricted stock units vest on each of the first and second anniversary of the date of grant, subject to Mr. Semerjian's continued service as the Company's President and Chief Executive Officer. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.